Cephalosporin-resistant Pneumococci and Sickle Cell Disease

Martha L. Miller*¹, Caroline A. Obert*¹, Geli Gao*, Najat C. Daw*, Patricia Flynn*, and Elaine Tuomanen*

Author affiliations: *St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Table 2

Multilocus sequence types of penicillin- and cephalosporin-resistant isolates*

Strain	Serotype	Allele numbers							Sequence type	Resistance		MIC values
Strain	Serotype	aroE	gdh	gki	recP	spi	xpt	ddl	Sequence type	PNV	CTX	PNV	CTX
38	3	8	37	9	29	2	12	NA	Novel	I	S	0.38	0.50
3	3	7	15	2	10	6	1	22	180	S
52	4	10	5	4	5	13	10	18	205	S
46	4	10	5	4	5	13	10	18	205	S
61	4	16	13	4	4	6	10	18	899	S
48	6	8	37	9	29	2	12	53	344	I	S	0.38	0.19
1	6	7	6	9	2	6	1	67	384	I	I	1.00	0.75
49	6	5	7	4	10	10	1	27	460	I	NA	0.38
63	6	5	7	4	10	10	1	27	460	I	S	0.38	0.50
35	6	1	25	1	8	15	20	14	660	I	I	1.00	0.75
81	6	1	25	72	1	15	20	28	690	I	S	0.094	0.094
84	6	2	13	8	6	6	3	NA	1754	I	NA	0.25
75	6	7	25	4	4	15	20	NA	Novel	I	S	0.094	0.094
13	6	1	5	4	5	5	3	101	NT3	I	S	0.38	0.19
29	6	1	5	4	5	5	3	101	NT3	I	S	0.94	0.25
19	6	7	6	9	2	6	1	67	384	R	R	3.00	3.00
33	6	7	6	1	2	6	15	14	146	S
37	6	7	6	1	2	6	15	14	146	S
40	6	7	6	1	2	6	15	14	146	S
45	6	7	6	1	2	6	15	14	146	S
39	6	7	13	8	6	10	6	14	176	S
76	6	7	15	2	10	6	1	22	180	S
44	6	1	5	1	5	1	1	8	425	S
85	6	7	25	4	4	15	20	1	647	S
30	6	1	25	72	1	15	20	28	690	S
43	6	1	25	72	1	15	20	28	690	S
31	6	7	61	1	1	17	1	NA	1752	S
4	11	2	5	29	12	16	3	14	62	S
20	11	2	5	29	12	16	3	14	62	S
22	14	2	8	7	4	6	1	1	67	R	I	4.00	1.00
27	14	2	8	7	4	6	1	1	67	R	I	4.00	1.00
57	14	2	8	7	4	6	1	1	67	R	I	2.00	1.00
59	14	2	8	7	4	6	1	1	67	R	I	3.00	1.50
74	14	1	5	4	5	5	27	8	13	S
56	14	7	5	1	8	14	11	14	124	S
83	14	7	5	1	8	14	11	14	124	S
28	15	8	6	14	4	17	4	14	1755	S
69	15	8	13	1	4	17	4	14	1757	S
71	15	8	13	1	4	17	4	14	1757	S
60	19	8	13	14	4	17	4	14	199	I	S	0.125	0.064
70	19	8	13	14	4	17	4	14	199	I	S	0.190	0.094
79	19	8	13	14	4	17	4	14	199	I	S	0.125	0.064
80	19	8	13	14	4	17	4	14	199	I	S	0.094	0.064
24	19	15	16	19	15	6	20	26	236	I	S	0.25	0.25
34	19	15	16	19	15	6	20	26	236	I	S	0.25	0.25
65	19	15	16	19	15	6	20	26	236	I	I	1.00	0.75
42	19	8	20	14	4	17	4	14	1756	I	S	0.190	0.094
77	19	8	20	14	4	17	4	14	1756	I	S	0.125	0.094
78	19	8	20	14	4	17	4	14	1756	I	S	0.190	0.064
41	19	15	NA	NA	NA	6	NA	NA	Novel	I	S	0.25	0.19
32	19	1	10	4	1	9	3	8	43	S
15	19	8	13	14	4	6	4	14	876	S
68	22	1	1	4	1	18	58	17	433	S
2	23	1	8	6	2	6	4	6	37	I	R	1.00	1.50
53	23	1	8	6	2	6	4	6	37	I	R	0.125	1.50
26	23	1	8	6	2	6	4	6	37	R	R	4.00	6.00
47	23	1	8	6	2	6	4	6	37	R	R	8.00	8.00
62	23	1	8	6	2	6	4	6	37	R	R	3.00	8.00
58	23	1	8	6	2	6	4	NA	1753	R	R	3.00	8.00
86	23	1	8	9	2	6	4	6	439	S
14	23	13	8	9	2	6	4	6	1499	S
55	ND	29	33	19	1	36	22	31	447	S
66	ND	5	5	6	1	9	10	14	547	S
25	ND	7	9	NA	1	14	48	14	Novel	S

*PNV, penicillin V; CTX, cefotaxime; S, susceptible; I, intermediate; R, resistant; NT, nontypeable; NA, not available; ND, not done.

Main Article

¹These authors contributed equally to this study.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

File Formats Help:

How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?

Page created: April 23, 2012
Page last updated: April 23, 2012
Page last reviewed: April 23, 2012
Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)

Ahead Of Print

Past Issues

Related Information

Additional Resources

Volume 11, Number 8—August 2005

Research